Jyong Biotech (NASDAQ:MENS) Trading Up 9.1% - What's Next?

Key Points

• Jyong Biotech's stock price increased by 9.1% to $59.00, following a previous close of $54.10, despite a significant drop in trading volume.
• The company's 50-day simple moving average stands at $30.26, indicating potential for future growth.
• Wall Street Zen recently upgraded Jyong Biotech to a "hold" rating, suggesting a more favorable outlook from analysts.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s share price was up 9.1% during trading on Wednesday . The stock traded as high as $59.03 and last traded at $59.00. Approximately 27,876 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 184,802 shares. The stock had previously closed at $54.10.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Jyong Biotech to a "hold" rating in a report on Monday, June 30th.

Jyong Biotech Stock Performance

The firm's 50-day simple moving average is $30.26.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.